Compare Ginkgo Bioworks Holdings Inc (DNA) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Matson Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Matson Inc trades at $210.44 (market cap $6.38B). The key difference: Matson Inc is far larger — about 10.8× Ginkgo Bioworks Holdings Inc's market cap, and Matson Inc pays a 0.72% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | MATX | |
|---|---|---|
Market Cap | $590.53M | $6.38B |
Sector | Health | Technology |
52-Week High | $16.14 | $210.95 |
52-Week Low | $5.48 | $88.05 |
Enterprise Value | $627.78M | $6.98B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Matson (MATX) trades at $205.15, up 0.19% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 12.92% net income margin and consistent earnings beats in recent quarters. Recent developments include a dividend increase to $0.38 per share and progress on its LNG-powered vessel construction program, highlighting operational strength and shareholder returns.
The outlook for MATX is positive, supported by niche Pacific shipping routes and resilient earnings. Key opportunities include growth in expedited China service and share repurchases. Risks involve exposure to trade volatility and potential margin pressure from higher costs. Analyst consensus is bullish with 64% buy ratings, but investors should monitor global trade flows and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
